Table 4.
NRPs with both antimicrobial and anticancer potential from marine microbes.
| Sr. No. | NRPs | Chemical architecture | Source | Biological target | Biological active value (MIC/IC50/GI50/ID50/ED50) | References |
|---|---|---|---|---|---|---|
| 1. | Lajollamycin (235) | Spiro-β-lactone-γ-lactam | Streptomyces nodosus | Drug resistant gram-positive bacteria/ | 2–20 μg/mL | Manam et al., 2005 |
| murine melanoma cell line B16-F10 | EC50 of 9.6 μM | |||||
| 2. | Ariakemicins A-B (236-237) | Linear peptide | Rapidithrix sp | S. aureus/ | 0.46 μg/mL | Oku et al., 2008a |
| human lung cancer cells (A549) and baby hamster kidney cells | IC50 values of 25 and 15 μg/mL | |||||
| 3. | Ieodoglucomide A-B (238-239) | Glycolipopeptide | Bacillus licheniformis | Antibacterial/lung cancer and stomach cancer cell lines | GI50 values of 25.18 and 17.78 μg/mL | Tareq et al., 2012 |
| 4. | Halolitoralin A (240) Halolitoralins B (241) C (242) | Cyclic hexapeptide Cyclic tetrapeptide | Halobacillus litoralis | Candida albicans and Tricophyton rubrum/human gastric tumor | 20, 30, 30 μg/mL and 25, 35, 40 μg/mL | Yang et al., 2002 |
| 5. | Mojavensin A (243) | Lipopeptide | Bacillus mojavensis | Valsa mali, cucumerinum, and Fusarium verticillioides/ | 2 mg /mL | Ma et al., 2012 |
| HL-60 | IC50 of 100 | |||||
| 6. | Marthiapeptide A (244) | Cyclic peptide | Marinactinospora thermotolerans | SF-268 (glioblastoma), MCF-7 (breast), NCI-H460 (lung), HepG2 (hepatocarcinoma)/ | 0.38–0.52 μM | Zhou et al., 2012 |
| gram-positive bacteria | ||||||
| 7. | Linear heptapeptide (245) | Heptapeptide | Paenibacillus profundus | SK-MEL-28 cell / | 3.07 μM/ | Kalinovskaya et al., 2013 |
| S. aureus, S. epidermis B. subtilis and Enterococcus faecium | ZOI = 24 mm, 20 mm,28 mm, 11 mm | |||||